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In this paper, deep learning is coupled with explainable artificial intelligence techniques for the 
discovery of representative genomic sequences in SARS‑CoV‑2. A convolutional neural network 
classifier is first trained on 553 sequences from the National Genomics Data Center repository, 
separating the genome of different virus strains from the Coronavirus family with 98.73% accuracy. 
The network’s behavior is then analyzed, to discover sequences used by the model to identify SARS‑
CoV‑2, ultimately uncovering sequences exclusive to it. The discovered sequences are validated on 
samples from the National Center for Biotechnology Information and Global Initiative on Sharing All 
Influenza Data repositories, and are proven to be able to separate SARS‑CoV‑2 from different virus 
strains with near‑perfect accuracy. Next, one of the sequences is selected to generate a primer set, and 
tested against other state‑of‑the‑art primer sets, obtaining competitive results. Finally, the primer is 
synthesized and tested on patient samples (n = 6 previously tested positive), delivering a sensitivity 
similar to routine diagnostic methods, and 100% specificity. The proposed methodology has a 
substantial added value over existing methods, as it is able to both automatically identify promising 
primer sets for a virus from a limited amount of data, and deliver effective results in a minimal amount 
of time. Considering the possibility of future pandemics, these characteristics are invaluable to 
promptly create specific detection methods for diagnostics.
The Coronaviridae family presents a positive sense, single-strand RNA genome. These viruses have been iden-
tified in avian and mammal hosts, including humans. Coronaviruses have genomes from 26.4 kilo base-pairs 
(kbps) to 31.7 kbps, with G + C contents varying from 32 to 43%; human-infecting coronaviruses belonging to 
this family include SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-229E, HCoV-NL63 and HCoV-HKU11. In 
December 2019, SARS-CoV-2, a novel, human-infecting Coronavirus was identified in Wuhan, China, using Next 
Generation Sequencing (NGS)2. As of the 12th August of 2020, the new SARS-CoV-2 has 20,162,474 confirmed 
cases across almost all countries, with 3,641,603 cases in the European  region3. In addition, SARS-CoV-2 has an 
estimated mortality rate of 3–4%, and it is spreading faster than SARS-CoV and MERS-CoV4.
As a typical RNA virus, new mutations appear every replication cycle of Coronavirus, and its average evo-
lutionary rate is roughly  10–4 nucleotide substitutions per site each  year2. In the specific case of SARS-CoV-2, 
RT-qPCR testing using primers in ORF1ab and N genes have been used to identified the infection in  humans5. 
This method has come into question; Yang et al. in a study from 866 respiratory specimens showed that for 0–7 
days after onset of illness, the sputum samples had a negative rate of 11.1% in severe and 17.8% in mild cases, 
follow by 26.7% and 27.0% in nasal swabs and finally 40% and 38.7% for throat  swabs6. Zhao et al. reports that 
35.2% of 173 patients did not show positive in RT-PCR  test7, which has been further explored by Arevalo et al.8 
and Woloshin et al.9. These problems could be the result of the variation of viral RNA sequences within virus 
species, and the viral load in different anatomic  sites10. It has been noted that, population mutation frequency 
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of site 8872 located in ORF1ab gene and site 28,144 located in ORF8 gene gradually increased from 0 to 29% as 
the epidemic  progressed11. Apart from the false negative test problems, SARS-CoV-2 assays can yield a small 
portion of false positives through nonspecific detection of other Coronaviruses, as the virus is closely related 
to other Coronavirus  organisms12. In addition, SARS-CoV-2 may be present with other respiratory infections, 
hindering its  identification13,14.
Thus, it is fundamental to improve existing diagnostic tools to contain the spread. For example, diagnos-
tic tools combining computed tomography (CT) scans with deep learning have been proposed, achieving an 
improved detection accuracy of 82.9%15. Another solution being used for studying SARS-CoV-2, is sequencing 
of the viral complementary DNA (cDNA). For example, we can use this sequencing data with cDNA, resulting 
from the PCR of the original viral RNA; e.g. Real-Time PCR amplicons to identify the SARS-CoV-216.
Classification using viral sequencing techniques is mainly based on alignment methods such as  FASTA17 
and  BLAST18. These methods rely on the assumption that cDNA sequences share common features, and their 
order prevails among different  sequences19,20. However, these methods suffer from the necessity of needing base 
sequences for the  detection21. Nevertheless, it is necessary to develop innovative improved diagnostic tools that 
target the genome to improve the identification of pathogenic variants, as sometimes several tests are needed 
to have an accurate diagnosis. Therefore, as an alternative, deep learning methods have been suggested for clas-
sification of DNA sequences. The advantage of these methods are that they do not need pre-selected features to 
identify or classify DNA sequences. Deep Learning has been efficiently used for classification of DNA sequences, 
using one-hot label encoding and Convolutional Neural Networks (CNN)22,23, albeit the examples in literature 
are featuring DNA sequences of length up to 500 bps, only.
In particular, for the case of viruses, NGS genomic samples might not be identified by BLAST, as there are no 
reference sequences valid for all genomes, as viruses have high mutation  frequency24. Alternative solutions based 
on deep learning have been proposed to classify viruses, by dividing sequences into pieces of fixed length, ranging 
from 300  bps24 to 3000  bps25. However, this approach has the negative effect of potentially ignoring part of the 
information contained in the input sequence, that is disregarded if it cannot completely fill a piece of fixed size. 
The global impact of SARS-CoV-2 prompted researchers to apply effective alignment-free methods to the clas-
sification of the virus: for example,  in26 the authors propose the use of Machine Learning Digital Signal Processing 
for separating the virus from similar strains, with remarkable accuracy. Nevertheless, there is no human-readable 
information that can be extracted from their black-box procedure, so the biological insight provided by their 
approach is limited. In order to offer further understanding to experts, techniques from the field of explainable 
AI (XAI)27,28 could be potentially effective; and it is interesting to remark that similar consideration specifically 
for the medical domain have already appeared in  literature29.
Given the impact of the world-wide outbreak, international efforts have been made to simplify the access to 
viral genomic data and metadata through international repositories, such as the National Genomics Data Center 
(NGDC)  repository11, the National Center for Biotechnology Information (NCBI)  repository30 and the Global 
Initiative on Sharing All Influenza Data (GISAID)  repository31, expecting that the ease of access to information 
would make it possible to develop medical countermeasures to control the disease worldwide, as it happened in 
similar cases  earlier32–34. Thus, taking advantage of the available information of international resources without 
any political and/or economic borders, we propose an innovative system based on viral gene sequencing.
Using a CNN to separate Coronaviruses belonging to different  strains35, including SARS-CoV-2, we apply 
techniques inspired by XAI in computer vision to discover representative cDNA sequences that the network uses 
to classify SARS-CoV-2. We then validate the discovered sequences on datasets not used during the training of 
the CNN, and show how to exploit them to create a novel, highly informative set of sequence features (e.g. viral 
sequences). Such sequences can be later inspected and analyzed by human experts. Experimental results show 
that the new set of sequence features leads traditional, simple classifiers, to correctly assess SARS-CoV-2 with 
remarkable accuracy (> 99%). A few of the discovered sequences also possess the correct characteristics for 
potentially becoming primers, as just checking for their presence in samples is enough to specifically identify 
SARS-CoV-2. Laboratory testing on the most promising sequences identified, showed that the primers found by 
our approach can be a viable alternative to the commonly adopted primers at the time of writing. These results 
could pave the way to an automatic procedure for the design of primers, see Fig. 1 for the proposed workflow.
Results
CNN classification and feature construction. The trained CNN described in the “Methods” section 
obtained a mean accuracy of 98.73% in a 10-fold stratified cross-validation. Observing the confusion matrix for 
the 5 considered classes, reported in Fig. 2 it is remarkable to notice that even samples from underrepresented 
classes were mostly correctly positioned. Such an encouraging result can indicate that the network was routinely 
able to uncover meaningful sequences to separate the different classes of viruses.
Once the network is trained, in a first analysis, we plot the inputs and outputs of the convolutional layer, to 
visually inspect for patterns. As an example, in Fig. 3a we report the visualization of the first 1250 bps of each of 
the 553 samples from the  NGDC11 repository.
Since each filter in the network slides a 21-bps window over the input, and for each step produces a single 
value, the output of a filter is a sequence of values in (0, 1). The output of the max pooling for each of the 12 
filters is then further inspected for patterns. It is noticeable how samples belonging to different classes can be 
already visually distinguished. At this step, we identify filter 0 as the most promising, as it seems to focus on a 
few relevant points in the genome, that could correspond to meaningful cDNA sequences.
Given this data, it is now possible to identify the 21-bps sequences that obtained the highest output values 
in the max pooling layer of filter 0, in a section of 148 positions. This process results in 210 (31,029 divided by 
148) max pooling features, each one identifying the 21-bps sequence that obtained the highest value from the 
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convolutional filter, in a specific 148-position interval of the original genome: the first max pooling feature will 
cover positions 1–148, the second will cover position 149–296, and so on. We show the complete set of max 
pooling features for the complete data 4410 (210*21) arranged one after the other, in Fig. 3b. The CNN archi-
tecture is described in the methods section, the visualization of the filter, and max pooling are available in the 
Supplementary Materials, Section 1.
Analyzing the different sequence values appearing in the max pooling feature space, we get a total of 3827 
unique 21-bps cDNA sequences, that can potentially be informative for identifying different virus strains. For 
example, sequence AGG TAA CAA ACC AAC CAA CTT is only found inside the class of SARS-CoV-2, in 59 
out of the 66 available samples. Sequence CAC GAG TAA CTC GTC TAT CTT is present again only in SARS-
CoV-2, in 63 out of the 66 samples.
Figure 1.  On the left, (a) shows the proposed workflow for the automated design of primers for viruses. On the 
right, (b) summarizes the different experiments reported in the paper, along with the datasets used in each trial.
4
Vol:.(1234567890)
Scientific Reports |          (2021) 11:947  | https://doi.org/10.1038/s41598-020-80363-5
www.nature.com/scientificreports/
The combination of the convolutional and max pooling layer allows the CNN to identify sequences even 
if they are slightly displaced in the genome (by up to 148 positions in the genome). Thus, we create a table of 
feature appearance of each of the sequences selected from the previous step. This results in a set of features able 
to differentiate SARS-CoV-2 from other viruses.
The experiments presented in the following subsections to validate our method have different objectives and 
make use of different datasets. A summary of all the experiments and datasets used is shown in Fig. 1.
Identifying SARS‑CoV‑2. Recapitulating the results of experiments 1–4 (see Fig.  1), we discovered 12 
meaningful 21-bps sequences that best characterize SARS-CoV-2. For all the analyzed data, these sequences 
appear only in SARS-CoV-2 samples and not in any other viruses, as summarized in Table 1. Remarkably, our 
results outperform earlier publications using machine learning for identifying SARS-CoV-2 (see for  example26), 
with the added benefit of producing human-readable results instead of a plain black box classifier.
Laboratory validation of the candidate primer set. We calculated the frequency of appearance of 
different primer sets’ sequences used in SARS-CoV-2 RT-PCR tests developed by World Health Organization 
(WHO) referral laboratories, and compared it to our primer design on the GISAID dataset (Table 2). All of the 
sequences have a frequency of appearance of > 99% , with the exception of CHINA-CDC-N-F, with a 68.52%. 
This is consistent with the percentage of genomes with mutation in the primer region, as stated by latest GISAID 
update summary of August 11th,  202031. For the in-silico analysis of specificity, we compared all the primers 
sets’ sequences with the NCBI-B and NGDC dataset, and the results show that HKU-N-F, HKU-N-R, Charite-
E-F, Charite-E-R and US-CDC-N2-F are not specific to SARS-CoV-2, as they bind to SARS-CoV, too. The rest 
of the sequences, including our design, only appear in SARS-CoV-2. In summary, of the 8 different primer sets, 
3 of them appear to not be specific to SARS-CoV-2; and by frequency of appearance, our design is the 3rd best 
option among the remaining 5, considering the lowest frequency between the -F and -R primer. This is a remark-
able result, considering that the proposed primer set has been extracted by an almost completely automated 
procedure.
To validate the data obtained in-silico by laboratory methods, a conventional PCR was performed on cDNA 
obtained from RNA from SARS-CoV-2 and other human coronaviruses. In addition, RNAs from nasopharyngeal 
swabs from six patients previously diagnosed with SARS-CoV-2 infection and four patients negative for SARS-
CoV-2 by routine diagnostic  method5 were analyzed with the same conventional PCR (Fig. 4). Different dilutions 
of SARS-CoV-2 RNA were detected with similar sensitivity compared to the diagnostic reference assay. (Fig. 4, 
lanes 1–8). Our candidate primer set exclusively detected SARS-CoV-2 and did not amplify RNA from other 
human coronaviruses (Fig. 4, lanes 9–14). The candidate primer set was able to detect SARS-CoV-2 RNA from 
patient samples previously found positive for SARS-CoV-2, but not in patients previously found negative (Fig. 4, 
lanes 15–24). Although further validation will be required to develop this candidate primer set into a diagnostic 
assay, our results clearly demonstrate the power of our method to select potential sequences for further validation.
Discussion
Being able to reliably identify SARS-CoV-2 and distinguish it from other similar pathogens is important to con-
tain its spread. The time of processing samples and the availability of reliable diagnostic tests is a challenge dur-
ing an outbreak. Developing innovative diagnostic tools that target the genome to improve the identification of 
pathogens, can help reduce health costs and time to identify the infection, instead of using unsuitable treatments 
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or testing. Moreover, it is necessary to perform an accurate classification to identify the different species of 
Coronavirus, the genetic variants that could appear in the future, and the co-infections with other pathogens.
Given the high transmissibility of the SARS-CoV-2, the proper diagnosis of the disease is urgent, to stop the 
virus from spreading further. Considering the false negatives given by the standard RT-qPCR detection, bet-
ter implementations such as using deep learning are necessary in order to properly detect the virus. While the 
accuracy of current RT-qPCR testing is around 70%, and CT scans with deep learning go up at 83%, we believe 
that the use of the sequences detected by a CNN-based methodology has the potential to improve the accuracy 
of the diagnosis.
Our results, show that by targeting one out of the 12 selected 21-bps specific sequences, we are able to dis-
tinguish SARS-CoV-2, from any other virus (> 99%). Further testing is necessary to confirm these promising 
results so it is essential to create multidisciplinary groups that work to stop the outbreak. Finally, as an interest-
ing remark, by comparing the discovered sequences against other hosts, we noticed that from the 12 sequences 
Figure 3.  Input 3a, and output 3b of the methodology in colored pixels represent bases: G = green, C = blue, 
A = red, T = orange, missing = black. The data is separated by class SARS-CoV1: SARS-CoV, SARS-CoV P2, 
SARS-CoV HKU-39849 and SARS-CoV GDH-BJH01. For visualization purposes we do not show HCov-EMC 
and HCoV-4408, given the number of samples. From visual inspection, it is possible to notice the similarity of 
patterns between samples belonging to the same class.
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exclusive to SARS-CoV-2, one of them appears in 13 of 17 samples from Manis Javanina. In contrast, 5 of the 
sequences of SARS-CoV-2 appear in the only sample available from Rhinolophus Affinis and 11 out of 12 in 2 
Canine samples (Table 1). This is consistent with the findings of Zhang et al.36,37, and could point to the zootonic 
origin of the virus. Nevertheless, more data is necessary.
As a result of the high density populations, and ever growing interaction between people, it is possible that 
other pandemics may occur. We believe that our methodology has a substantial added value over traditional 
methods, because it is a fast method and only limited set of viral sequencing data is needed. Moreover, this pro-
cedure led to a primer set with a very high specificity for SARS-CoV-2 with at least the same accuracy as the best 
primers sets in the world developed by WHO referral laboratories. Thus, thinking forward, our methodology can 
be applied in future viral pandemics to speed up the development of accurate detection methods for diagnosis 
and thereby contribute to limit the spread of a virus.
Methods
The CNN used during all the experiments is composed of one convolutional layer with 12 different filters or 
weights (each with window size 21, and an even padding of 10 steps on each side) with maxpooling (pool size 
148 and stride 1), a fully connected layer (196 rectified linear units with dropout probability 0.5), and a final 
softmax layer with 5 units, to differentiate the different classes of Coronavirus strains. The optimizer used is 
Adaptive Momentum (ADAM)38, with learning rate 10−5 and a batch size of 50 samples, run for 1000  epochs35. 
A graphical summary of the CNN used in the experiments is reported in Fig. 5.
The convolutional layer of the network, in simple terms, is analyzing subsequences of 21 base pairs that can 
appear in different points of the virus genome. We selected 21 as designed primers for RT-PCR tests have a 
length of 18–22 bps normally. The pool size of the maxpooling represents the interval in which a specific 21-bps 
Table 1.  Percentage of appearance for each of the 12 discovered 21-bps sequences across the different datasets, 
and comparison to similar viruses in nature and other hosts. 121-bps sequence resulting from experiment 2.  2
21-bps sequence resulting from experiment 3.
Source GISAID NCBI NCBI NGDC NGDC GISAID GISAID GISAID GISAID
Virus SARS-CoV-2 Other Taxa SARS-CoV-2 Other Taxa SARS-CoV-2 Betacoronavirus Betacoronavirus Betacoronavirus Betacoronavirus
Host Homo Sapiens Homo Sapiens Homo Sapiens Homo Sapiens Homo Sapiens Manis javanica Rhinolophus affinis Canine Felis Catus
# Samples 52,645 20,572 32 487 96 17 1 2 6
1CAC GTA 
GGA ATG TGG 
CAA CTT 
99.84% 0.00% 100.00% 0.00% 97.92% 0.00% 100.00% 100.00% 50.00%
1TAT TAG TGA 
TAT GTA CGA 
CCC 
99.73% 0.00% 100.00% 0.00% 97.92% 0.00% 0.00% 100.00% 50.00%
1AAT GAA TTA 
TCA AGT TAA 
TGG 
99.94% 0.00% 100.00% 0.00% 96.88% 76.47% 0.00% 100.00% 66.67%
1CAA CTT TTA 
ACG TAC CAA 
TGG 
99.55% 0.00% 100.00% 0.00% 97.92% 0.00% 0.00% 100.00% 50.00%
1CTA AAG CAT 
ACA ATG TAA 
CAC 
99.76% 0.00% 100.00% 0.00% 100.00% 0.00% 0.00% 100.00% 66.67%
1TAG CAC TCT 
CCA AGG GTG 
TTC 
99.57% 0.00% 100.00% 0.00% 97.92% 0.00% 0.00% 100.00% 66.67%
1TGC CAC TTG 
GCT ATG TAA 
CAC 
99.90% 0.00% 100.00% 0.00% 97.92% 0.00% 100.00% 100.00% 66.67%
1CAT CTA CTG 
ATT GGA CTA 
GCT 
99.79% 0.00% 100.00% 0.00% 97.92% 0.00% 100.00% 100.00% 50.00%
1TGA GCA 
GTG CTG ACT 
CAA CTC 
99.56% 0.00% 100.00% 0.00% 98.96% 0.00% 0.00% 100.00% 66.67%
1GAT GGT 
CAA GTA GAC 
TTA TTT 
99.69% 0.00% 100.00% 0.00% 96.88% 0.00% 0.00% 100.00% 66.67%
2AAT AGA AGA 
ATT ATT CTA 
TTC 
99.73% 0.00% 100.00% 0.00% 96.88% 0.00% 100.00% 100.00% 66.67%
2CGA TAA CAA 
CTT CTG TGG 
CCC 
99.06% 0.00% 100.00% 0.00% 97.92% 0.00% 100.00% 50.00% 50.00%
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Table 2.  Comparison of primer sets developed by WHO referral labs, against the primer set obtained by 
the proposed approach, listed as UtrechtU-ORF3a. The Frequency column indicates frequency of appearance 
of the sequence among samples of the GISAID dataset. The Specific (Yes/No) column shows whether the 
sequence appears to be unique to SARS-CoV-2 samples, or can also be found in other viruses, according to the 
evaluation on the NCBI-B and NGDC datasets.
Primer Sequence Frequency (%) Specific (Yes/No)
Charite-E-F 5′-ACA GGT ACG TTA ATA GTT AAT AGC GT-3′ 99.90 No
Charite-E-R 5′-ATA TTG CAG CAG TAC GCA CAC A-3′ 99.90 No
CHINA-CDC-ORF1ab-F 5′-CCC TGT GGG TTT TAC ACT TAA-3′ 99.90 Yes
CHINA-CDC-ORF1ab-R 5′-ACG ATT GTG CAT CAG CTG A-3′ 99.59 Yes
HKU-N-F 5′-TAA TCA GAC AAG GAA CTG ATT A-3′ 99.56 No
HKU-N-R 5′-CGA AGG TGT GAC TTC CAT G-3′ 99.58 No
US-CDC-N1-F 5′-GAC CCC AAA ATC AGC GAA AT-3′ 99.71 Yes
US-CDC-N1-R 5′-TCT GGT TAC TGC CAG TTG AAT CTG-3′ 99.57 Yes
US-CDC-N2-F 5′-TTA CAA ACA TTG GCC GCA AA-3′ 99.43 No
US-CDC-N2-R 5′-GCG CGA CAT TCC GAA GAA-3′ 99.74 Yes
UtrechtU-ORF3a-F 5′-TAG CAC TCT CCA AGG GTG TTC-3′ 99.57 Yes
UtrechtU-ORF3a-R 5′-GCA AAG CCA AAG CCT CAT TA-3′ 99.48 Yes
US-CDC-N3-F 5′-GGG AGC CTT GAA TAC ACC AAA A-3′ 99.09 Yes
US-CDC-N3-R 5′-TGT AGC ACG ATT GCA GCA TTG-3′ 99.72 Yes
CHINA-CDC-N-F 5′-GGG GAA CTT CTC CTG CTA GAA T-3′ 68.52 Yes
CHINA-CDC-N-R 5′-CAG ACA TTT TGC TCT CAA GCT G-3′ 99.20 Yes
Figure 4.  Laboratory validation of the candidate primer set by conventional PCR. MM, molecular weight 
marker; lanes 1–8, 10-fold dilutions of SARS-CoV-2 RNA (corresponding to Ct values 26–39 in the diagnostic 
reference assay); lanes 9–14, RNA from different human coronaviruses (hCoV-OC43, hCoV-229E, hCoV-NL63, 
MERS-CoV, SARS-1, SARS-CoV-2, respectively); lanes 15, 16, 17, 19, 20, 21, patient samples previously found 
positive for SARS-CoV-2; lanes 18, 22, 23, 24, patient samples previously found negative for SARS-CoV-2.
Figure 5.  Graphical representation of the architecture of the CNN used in the experiments.
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sequence can be recognized (in this case, 148 positions). Through the training process, the convolutional layer 
is de-facto learning new features to characterize the problem, directly from the data. In this specific case, the 
new features are 21-bps sequences that can more easily separate different virus strains. By analyzing the result 
of each filter in a convolutional layer, and how its output interacts with the corresponding max pooling, it is 
possible to detect human-readable sequences of base pairs that might provide domain experts with relevant 
information. It is important to notice that these sequences are not bound to specific locations of the genome; 
thanks to its structure, the CNN is able to detect them and recognize their importance even if their position is 
displaced in different samples.
We downloaded 583 sequences (*.fasta files) from the NGDC on March 15th, 2020 (Table 3). We divided 
the samples into 5 classes, taking into account both the number of available samples, and the seasonality of the 
related diseases. SARS-CoV-2 on its own as class 0, as the main objective is to separate this virus from all the 
others. The 240 samples from MERS-CoV/HCoV-EMC were assigned to class 1, as the related disease is mostly 
geographically limited to areas of Saudi  Arabia39. HCoV-OC43, HCoV-229E and HCoV-NL63 have been reported 
to have winter seasonality, while HCoV-HKU1 has spring-summer seasonality. Nevertheless, there are instances 
where HCoV-NL63 had a spring-summer seasonality closer to HCoV-HKU140–42. Thus, also considering the 
number of samples, we grouped together HCoV-OC43, and HCoV-229E as class 2, while HCoV-HKU1 and 
HCoV-NL63 were grouped as class 3. We included HCoV-4408 in class 2 as well, as there were only 2 samples 
available: HCoV-4408 is subgroup A of the betacoronavirus genus, as HCoV-OC4343. Finally, as we deemed 
important to distinguish SARS-CoV-2 from SARS-CoV, SARS-CoV was assigned to its own class (class 4) even 
if only 10 samples were available.
We left out 30 SARS-CoV-2 sequences and then performed a 10-fold stratified cross-validation, with the 
remaining data divided into 80% training (8 folds), 10% validation (1 fold), 10% testing (1 fold). The stratified 
cross-validation preserves the ratio of classes in the original dataset for each fold, thus making the final accuracy 
more reliable.
Identifying SARS‑CoV‑2. Experiment 1: Validation on the NGDC dataset. We downloaded the dataset 
from the NGDC  repository11 on March 15th, 2020. We removed repeated sequences and applied the procedure 
to translate the data into the sequence feature space. This leaves us with a frequency table of 3827 features (21-
bps sequences) with 583 samples (Table 3 (left)). Next, we ran a state-of-the-art feature selection  algorithm45,46, 
to reduce the sequences needed to identify different virus strain to the bare minimum. Remarkably, we are then 
able to correctly differentiate all the coronavirus (MERS-CoV, SARS-CoV-2, SARS-CoV-1, etc) samples using 
only 53 of the original 3827 sequences, obtaining a 100% accuracy in a 10-fold cross-validation with a simpler 
and more traditional classifier, such as Logistic Regression. The list of the 53 features is available in the Supple-
mentary Materials, Section 2.
Experiment 2: Validation on the NCBI dataset. We downloaded data from the  NCBI30 repository on March 
15th, 2020, with the following query: gene = “ORF1ab” AND host = “homo sapiens” AND “complete genome”. The 
query resulted in 407 non-repeated sequences (Table 3 (right)). We call this dataset NCBI-A, where 68 sequences 
belong to SARS-CoV-2. Then, we applied the procedure to translate the data into the set of sequence features, 
and we run the same state-of-the-art feature selection  algorithm45. The result is a list of 10 different sequences 
(Table 1), for which just checking for their presence is enough to differentiate between SARS-CoV-2 and other 
viruses in the dataset, with a 100% accuracy. Each of the sequences, in fact, only appears in SARS-CoV-2 sam-
ples.
Table 3.  Organism, assigned label, and number of samples in the unique sequences for the NGDC repository 
(left) and query: gene = “ORF1ab” AND host = “homo sapiens” AND “complete genome” in the NCBI repository 
(right). We use the NCBI organism naming  convention44.
Organism Label Number of samples Organism Label Number of samples
SARS-CoV-2 0 96 SARS-CoV-2 0 68
MERS-CoV 1 236 MERS-CoV 1 180
HCoV-EMC 1 4 HCoV-HKU1 1 13
HCoV-OC43 2 138 HCoV-OC43 1 105
HCoV-229E 2 22 HCoV-NL63 1 29
HCoV-4408 2 2 HCoV-4408 1 2
HCoV-NL63 3 58 HCoV-229E 1 3
HCoV-HKU1 3 17 HCoV-EMC 1 3
SARS-CoV 4 7 HAstV-VA1 1 1
SARS-CoV P2 4 1 HAstV-BF34 1 1
SARS-CoV HKU-39849 4 1 HMO-A 1 1
SARS-CoV GDH-BJH01 4 1 HAstV-SG 1 1
Total samples – 583 Total samples – 407
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Experiment 3: Further validation on the NCBI dataset. We downloaded data from  NCBI30 on March 17th, 2020, 
with the following query: “virus” AND host = “homo sapiens” AND “complete genome”, restricting the size from 
1000 to 35,000 bps (NCBI-B). The query returns 20,603 samples, of which only 32 belong to SARS-CoV-2, and 
20,571 are from other taxa, including Hepatitis B, Dengue, Human immunodeficiency, Human orthopneumovi-
rus, Enterovirus A, Hepacivirus C, Chikungunya virus, Zaire ebolavirus, Human respirovirus 3, Orthohepevirus 
A, Norovirus GII, Hepatitis delta virus, Mumps rubulavirus, Enterovirus D, Zika virus, Measles morbillivirus, 
Enterovirus C, Human T-cell leukemia virus type I, Yellow fever virus, Adeno-associated virus, rhinovirus (A, 
B and C), for a total of more than 584 other viruses (not considering strains and isolates). Then, we applied the 
procedure to translate the data into the sequence feature space and run the feature reduction  algorithm45. This 
results in 2 extra sequences of 21 bps: just by checking for their presence, we are able to separate SARS-CoV-2 
from the rest of the samples with a 100% accuracy (Table 1).
Experiment 4: Validation on the GISAID dataset. From the GISAID  repository31, we downloaded 53,183 
sequences available on August 10th, for SARS-CoV-2, from different countries, from there 52,645 have as < 1% 
Ns, high coverage and host = “homo sapiens”. Then, we calculated the frequency table of the 21-bps sequences 
obtained from experiments 2 and 3, to verify which sequences remain and could be used for detection. The 
appearance frequency of the target sequences among the samples in the GISAID dataset is reported in Table 1, 
second column. In addition, we downloaded 26 sequences from GISAID repository of other hosts (manis javan-
ica, rhinolophus affinis, canine and felis catus) to make a comparison in the sequences from experiment 2 and 3.
Laboratory validation of the candidate primer set. Experiment 5: Design of the candidate primer 
set. After the analysis carried out on the deep learning model, we ran an analysis with  Primer3plus47, to see 
which of the sequences could be used as a forward primer, using sample NCBI NC045512.2 as the reference 
SARS-CoV-2 sequence. We uncover the sequence TAG CAC TCT CCA AGG GTG TTC that shows a frequency 
of appearance of 99.57% in viral genomes available from different countries in  GISAID31 and 100.0% in the 
 NCBI30 datasets. Using the reference SARS-CoV-2 sequence, we identify that this discovered sequence is located 
between nucleotides 25,604 and 25,624 in the ORF3a gene. In SARS-CoV, this gene encodes a protein of 274 aa, 
that is related with necrotic cell  death48,49, chemokine production like interleukin 8 (IL-8) and RANTES/CCL5, 
NFκB activation resulting in an inflammatory  response50 and may play an important role in the virus life  cycle51. 
We design a specific primer set for detection of SARS-CoV-2 using  Primer3plus47. We use TAG CAC TCT 
CCA AGG GTG TTC as forward primer and GCA AAG CCA AAG CCT CAT TA as reverse primer, obtain-
ing an amplicon size of 179 bps. Then, we run an in-silico PCR test using FastPCR 6.752 with default parameters 
in NC045512.2 used as a reference SARS-CoV-2 sequence, this yields Tm = 56.2 ◦ C for the forward primer, 
Tm = 53.1 ◦ C for the reverse primer and Ta = 58 ◦C.
In addition, we calculated the frequency of appearance of different primers sets’ sequences used in SARS-
CoV-2 RT-qPCR tests developed by WHO referral laboratories and compared it to our primer design sequences 
in 52,645 sequences from the GISAID repository and the 583 samples of different coronaviruses from the NGDC 
dataset from experiment 1. The used primers set are developed by University of Hong Kong (HKU-N); Charite, 
Berlin, Germany (Charite-E); US-CDC, United States (US-CDC-N1,US-CDC-N2,US-CDC-N3) and China CDC, 
China (China-CDC-ORF1ab, China-CDC-N) (Table 2). We selected this primers as they are the ones more com-
monly used as stated in the GISAID status update of August 11, 2020. We do not consider degenerate primer sets.
Experiment 6: Validation of the candidate primer set in biological samples.. Viral RNA was isolated from cell-
cultured SARS-CoV-2, SARS-1, MERS-CoV, hCoV-NL63, hCoV-OC43, hCoV-229E, and from nasopharyngeal 
swabs from n = 10 patients by MagNA Pure LC (Roche Diagnostics, The Netherlands) using the total nucleic 
acid isolation kit. The RNA was converted into cDNA using SuperscriptIII (Thermo-Fisher Scientific, USA) and 
random hexamers. Subsequently, conventional PCR was performed on the cDNA using HotStar Taq DNA poly-
merase (Qiagen, The Netherlands) with 400 nM forward primer (5′-AG CAC TCT CCA AGG GTG TTC -3′) 
and 400 nM reverse primer (5′-GCA AAG CCA AAG CCT CAT TA-3′) and the following cycling conditions: 
15 min at 95◦ C, followed by 40 cycles of 1 min at 95◦ C, 1 min at 5 ◦ C and 1 min at 72◦ C. The PCR products were 
visualized by electrophoresis. The same RNA was used in a diagnostics reference assay by Corman et al.5 and the 
Cycle threshold values form this reference assay were used for estimating sensitivity.
Data availability
All the necessary scripts to reproduce the experiments are stored on the public GitHub repository: https ://
githu b.com/stepp enwol f0/prime rs-sars-cov-2. Due to storage limits, while the data to reproduce Experiment 1 
is included in the repository, for Experiments 2–5 only the IDs of the samples used are listed in file sample-
ids.xlsx. Given their IDs, samples for Experiments 2–5 can be downloaded from the corresponding open 
repositories: : GISAID (https ://www.gisai d.org/), NCBI (https ://www.ncbi.nlm.nih.gov/), NGDC (https ://bigd.
big.ac.cn/ncov/?lang=en).
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